BRIEF published on 09/12/2024 at 15:05, 2 months 8 days ago Change in the Chief Financial Officer at Biotest AG Chief Financial Officer Financial News Leadership Transition Biotest AG Martin Möller
PRESS RELEASE published on 09/12/2024 at 15:00, 2 months 8 days ago Change in the Chief Financial Officer at Biotest AG Biotest AG announces change in Chief Financial Officer with Martin Moller taking over as Interim CFO. Ainhoa Mendizabal Zubiaga to step down for personal reasons Chief Financial Officer Biotest AG Interim CFO Change Martin Möller
BRIEF published on 09/05/2024 at 09:05, 2 months 16 days ago Biotest AG Opens 13th Plasma Collection Center in Germany Germany Patient Advocacy Biotest AG Plasma Collection Medical Treatments
PRESS RELEASE published on 09/05/2024 at 09:00, 2 months 16 days ago Biotest AG opens 13th plasma collection center in Germany Biotest AG opens 13th plasma collection center in Germany to ensure long-term plasma supply. State-of-the-art center in Karlsruhe operated by Plasma Service Europe GmbH, a subsidiary of Biotest AG Donations Germany Biotest AG Plasma Collection Center Plasma Service Europe GmbH
BRIEF published on 08/28/2024 at 09:05, 2 months 24 days ago Dr. Jörg Schüttrumpf Resigns from Biotest AG Management Board Management Board Biotest AG Product Development Jörg Schüttrumpf Grifols Group
PRESS RELEASE published on 08/28/2024 at 09:00, 2 months 24 days ago Dr. Jörg Schüttrumpf resigns from the Management Board of Biotest AG Dr. Jörg Schüttrumpf resigns as Chief Scientific Officer of Biotest AG to focus on role as Chief Scientific Innovation Officer of Grifols Group, effective August 31, 2024 Resignation Management Board Biotest AG Grifols Group Dr. Jörg Schüttrumpf
BRIEF published on 08/06/2024 at 09:05, 3 months 15 days ago Biotest Sees 35% Sales Spike in First Half of 2024 Financial Results Revenue Growth FDA Approval Biotest Yimmugo®
PRESS RELEASE published on 08/06/2024 at 09:00, 3 months 15 days ago Biotest increases sales in the first half of 2024 by 35% to Euro 372 million Biotest AG reports 35% sales increase to Euro 372 million in H1 2024. EBIT reaches Euro 78.4 million. FDA approves Yimmugo® and BNL facility. Positive revenue and earnings growth Revenue Growth FDA Approval Sales Increase Biotest AG H1 2024
BRIEF published on 07/30/2024 at 08:05, 3 months 22 days ago Biotest Reports 35% Increase in Sales for First Half of 2024 Financial Results Revenue Increase FDA Approval Sales Growth Biotest AG
PRESS RELEASE published on 07/30/2024 at 08:00, 3 months 22 days ago Biotest increases sales in the first half of 2024 by 35% to Euro 372 million Biotest AG increases sales by 35% to Euro 372 million in the first half of 2024. EBIT reaches €78.4 million. FDA approval received. Strategic deal with Kedrion estimated to yield $1 billion in 7 years FDA Approval EBIT Sales Increase Biotest AG €372 Million
Published on 11/21/2024 at 14:15, 17 minutes ago neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Published on 11/21/2024 at 14:00, 32 minutes ago Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 32 minutes ago Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 32 minutes ago Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 14:16, 16 minutes ago EQS-Adhoc: LM PAY S.A. Announces Third Quarter 2024 Preliminary Results and Updated Guidance
Published on 11/21/2024 at 14:15, 17 minutes ago ZenaTech Signs Blue UAS and NDAA Compliant Supply Chain Partners to Sell to US Defense Branches and NATO Forces
Published on 11/21/2024 at 12:35, 1 hour 57 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 06:58, 7 hours 34 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 19 hours 12 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 47 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 47 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
